Temporal trends and current use of de novo belatacept in kidney transplant recipients in the United States-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Temporal trends and current use of de novo belatacept in kidney transplant recipients in the United States

Published:2021-11-29 Issue: Volume: Page:
ISSN:0902-0063
Container-title:Clinical Transplantation
language:en
Short-container-title:Clin Transplant

Author:

Karadkhele Geeta¹,Duneton Charlotte¹²,Garro Rouba³,Badell Idelberto Raul¹^ORCID,Pearson Thomas C.¹,Larsen Christian P.¹,Hogan Julien¹²^ORCID

Affiliation:

1. Emory Transplant Center, Department of Surgery Emory School of medicine Atlanta Georgia USA

2. Pediatric Nephrology Department Robert Debré Hospital, APHP Paris France

3. Pediatric Nephrology Division Department of Pediatrics Children's Healthcare of Atlanta Atlanta Georgia USA

Publisher

Wiley

Subject

Transplantation

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/ctr.14531

Reference17 articles.

1. Rational Development of LEA29Y (belatacept), a High‐Affinity Variant of CTLA4‐Ig with Potent Immunosuppressive Properties

2. De novo donor-specific antibodies in belatacept-treated vs cyclosporine-treated kidney-transplant recipients: Post hoc analyses of the randomized phase III BENEFIT and BENEFIT-EXT studies

3. A Phase III Study of Belatacept-based Immunosuppression Regimens versus Cyclosporine in Renal Transplant Recipients (BENEFIT Study)

4. A Phase III Study of Belatacept Versus Cyclosporine in Kidney Transplants from Extended Criteria Donors (BENEFIT-EXT Study)

5. Belatacept and Long-Term Outcomes in Kidney Transplantation

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Belatacept Versus Tacrolimus for Kidney Transplant Recipients of Deceased Donors With Acute Kidney Injury: US National Database Study;Transplantation;2024-09-04

2. IL-6 inhibition prevents costimulation blockade-resistant allograft rejection in T cell-depleted recipients by promoting intragraft immune regulation in mice;Nature Communications;2024-06-03

3. Costimulatory Blockade and Solid Organ Transplantation: The Past, Present, and Future;Kidney International Reports;2023-12

4. Siplizumab combination therapy with belatacept or abatacept broadly inhibits human T cell alloreactivity in vitro;American Journal of Transplantation;2023-10

5. Preservation of Antiviral Immunologic Efficacy Without Alloimmunity After Switch to Belatacept in Calcineurin Inhibitor–Intolerant Patients;Kidney International Reports;2023-01

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3